Breakthrough T1D Charts Course on Multiple Fronts to Advance Type 1 Diabetes Care

Breakthrough T1D, the organization formerly known as JDRF, held its inaugural Clinical & Research Congress in May 2026, signaling an evolution in how the organization connects researchers, clinicians, and the diabetes community. The event brought together leaders navigating the pipeline of emerging therapies and the practical challenges of getting them into clinical practice.

Anastasia Albanese-O'Neill, Ph.D., APRN, CDCES, serves as vice president of medical affairs at Breakthrough T1D. Her role centers on a specific challenge: accelerating the adoption of new therapies in real-world clinical settings. This includes raising awareness about early detection of Type 1 diabetes and helping people understand opportunities to participate in clinical trials.

Before joining Breakthrough T1D, Albanese-O'Neill was a professor of pediatrics and nursing at the University of Florida, where she maintained both a research program and active clinical practice. Her research has appeared in peer-reviewed journals including Diabetes Care, The Lancet, and Pediatric Diabetes. Beyond her professional work, Albanese-O'Neill has been a diabetes advocate since her daughter was diagnosed with Type 1 in 2002, a perspective that shapes her approach to improving care.

Sanjoy Dutta, Ph.D., chief scientific officer at Breakthrough T1D, oversees the organization's research efforts across several domains. These include screening for Type 1 diabetes risk, beta cell therapies, immunotherapies, glucose and metabolic control, and work on diabetes complications. The organization also pursues international partnerships to expand its reach and impact.

This multi-pronged approach reflects the reality that advancing Type 1 diabetes care requires progress on multiple scientific fronts—not just one breakthrough, but coordinated advancement across detection, prevention, cell therapy, and immune-system focused treatments.

Both Albanese-O'Neill and Dutta bring credentials grounded in peer-reviewed science and, in Albanese-O'Neill's case, direct clinical experience with diabetes patients. Albanese-O'Neill has testified before Congress and state legislatures and co-authored position statements on diabetes care in schools. In 2025, she received the Women in Leadership in Diabetes Award, and in 2023 was named Diabetes Care and Education Specialist of the Year by ADCES.

Origin: citybiz.co (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.